Who Paid My Doc
Jeanne Poole
Clinical Cardiac Electrophysiology Seattle, WA Medical Doctor
NPI 1073637732 CMS profile 184405
1959 Ne Pacific St, Seattle, WA 98195
General payments
$81,081
Research payments
$28,327
Ownership & investment interest
$0
Research they led as principal investigator
$82,335
Through program year 2025, Jeanne Poole of Seattle, WA is reported in the CMS Open Payments database as having received $81,081 across 85 general payments and $28,327 in research payments paid to them. Separately, studies naming them as principal investigator received $82,335 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 89th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $22,994 | 19 | |
| 2025 | Research | $1,278 | 2 | |
| 2024 | General | $39,115 | 24 | |
| 2024 | Research | $8,710 | 8 | |
| 2023 | General | $2,137 | 3 | |
| 2023 | Research | $12,889 | 8 | |
| 2022 | General | $83 | 1 | |
| 2022 | Research | $5,450 | 4 | |
| 2020 | General | $50 | 1 | |
| 2019 | General | $16,702 | 37 |
Beside peers
- Jeanne Poole
- Clinical Cardiac Electrophysiology median
- Middle half of Clinical Cardiac Electrophysiology
- National median
In program year 2025, general payments to Jeanne Poole were reported at $22,994. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.
Show as a table
| Year | Jeanne Poole | Clinical Cardiac Electrophysiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $16,702 | $2,361 | $585–$8,260 | $163 |
| 2020 | $50 | $993 | $247–$4,351 | $114 |
| 2021 | $0 | $1,185 | $326–$4,739 | $132 |
| 2022 | $83 | $2,073 | $554–$6,789 | $149 |
| 2023 | $2,137 | $2,568 | $759–$8,159 | $160 |
| 2024 | $39,115 | $2,557 | $703–$7,403 | $164 |
| 2025 | $22,994 | $2,462 | $733–$7,710 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 15 drugsPart D claims
435
Drug cost
$141,384
Branded share of claims
39.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 115 | $117,151 | |
| Savaysa Edoxaban Tosylate | Brand | 15 | $10,534 | |
| Dofetilide | Generic | 28 | $5,167 | |
| Tiazac Diltiazem Hcl | Brand | 12 | $2,162 | |
| Metoprolol Succinate | Generic | 92 | $1,349 | |
| Mexiletine Hcl | Generic | 11 | $1,066 | |
| Flecainide Acetate | Generic | 23 | $1,002 | |
| Amiodarone Hcl | Generic | 49 | $875 | |
| Diltiazem 24hr Er (Cd) Diltiazem Hcl | Brand | 11 | $731 | |
| Sotalol Sotalol Hcl | Brand | 20 | $471 |
The 10 drugs with the highest cost, of 15 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 32 billing codesPaid by Medicare
$54,329
Medicare patients
816
Services billed
1,672
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 72% | |
| Atrial fibrillation | 61% | |
| Heart failure | 52% | |
| Ischemic heart disease | 43% | |
| Arthritis | 37% | |
| Chronic kidney disease | 30% | |
| Diabetes | 25% | |
| Depression | 23% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
107 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Cardiac Electrophysiology in Washington
Gust Bardy
Clinical Cardiac Electrophysiology · Seattle, WA
Babak Nazer
Clinical Cardiac Electrophysiology · Seattle, WA
Maheer Gandhavadi
Clinical Cardiac Electrophysiology · Bellevue, WA
Toshimasa Okabe
Clinical Cardiac Electrophysiology · Seattle, WA
Darryl Wells
Clinical Cardiac Electrophysiology · Seattle, WA
Arun R Mahankali Sridhar
Clinical Cardiac Electrophysiology · Seattle, WA
Related records
Clinical Cardiac Electrophysiology in Washington
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Cardiac Electrophysiology
Everyone recorded under this specialty, nationwide.
Doctors in Washington
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.